Schreiber, Robin
Hori, Manami
Takahashi, Chisato
Rahman, Mohammad Sofiqur
Nakao, Ayane
Zhu, Shu
Zhu, Feiyu
Yoshida, Naoko http://orcid.org/0000-0001-5359-0225
Maekawa, Keiko
Kimura, Kazuko
Funding for this research was provided by:
Ministry of Health, Labour and Welfare (H30-医薬-一般-001)
Article History
Received: 20 December 2023
Accepted: 24 April 2024
First Online: 3 June 2024
Declarations
:
: The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
: The authors declare that they have no competing interests.
: This work was funded by the Ministry of Health, Labour and Welfare of the Japan Pharmaceuticals and the Medical Devices Regulatory Science Policy Research Program under grant number H30-iyaku-ippan-001.
: This study was made possible by the generous support of the Japanese Ministry of Health, Labour and Welfare, for which the authors express their gratitude. The authors thank SC Balkan Pharmaceuticals SRL (Singera, Republic of Moldova) for providing DANABOL 10 mg for purchase; DANABOL 10 mg was used as the standard formulation and control in this study. The authors thank the national regulatory authorities, in particular FDA Philippines, FDA Taiwan, and RP Tübingen, Germany as well as the municipality of Gaißach, Germany for their cooperation. The authors thank Edanz () for editing a draft of this manuscript. The contribution of RS was supported by the PhD “Monbukagakusho” scholarship from the Japanese Ministry of Education, Culture, Sports, Science and Technology in Japan.